"LEUKOTAC® has a role to play in the management of steroid-resistant acute graft-versus-host disease (SR-aGvHD) with a considerable decrease of mortality in these patients.
LEUKOTAC® will be used in SR-aGvHD with no doubt, because of our huge experience of this drug. Once it is available again, it will be administrated and we can think about its potential use in the first line of treatment"
Pr. Mauricette Michallet
Previously Head of Haematology Unit Lyon Civil Hospices, Today in charge of post cancer at the Centre Léon Bérard